Association of extremely high levels of high-density lipoprotein cholesterol with endothelial dysfunction in men

1. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High

density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62:707–714.

2. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery

disease (the PROCAM experience). Prospective Cardiovascular

Munster study. Am J Cardiol. 1992;70:733–737.

3. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein

cholesterol and cardiovascular disease. Four prospective American

studies. Circulation. 1989;79:8–15.

4. Rader DJ, Alexander ET, Weibel GL, Billheimer J, Rothblat GH. The

role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res. 2009;50(Suppl):S189–S194.

5. Yuhanna IS, Zhu Y, Cox BE, et al. High-density lipoprotein binding to

scavenger receptor-BI activates endothelial nitric oxide synthase. Nat

Med. 2001;7:853–857.

6. Navab M, Hama SY, Cooke CJ, et al. Normal high density lipoprotein

inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res. 2000;41:1481–1494.

7. Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. High-density

lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol. 1995;15:1987–1994.

8. Sugano M, Tsuchida K, Makino N. High-density lipoproteins protect

endothelial cells from tumor necrosis factor-alpha-induced apoptosis.

Biochem Biophys Res Commun. 2000;272:872–876.

9. Hirata A, Okamura T, Sugiyama D, et al. The relationship between

very high levels of serum high-density lipoprotein cholesterol and

cause-specific mortality in a 20-year follow-up study of Japanese general population. J Atheroscler Thromb. 2016;23:800–809.

10. Madsen CM, Varbo A, Nordestgaard BG. Extreme high high-density

lipoprotein cholesterol is paradoxically associated with high mortality

in men and women: two prospective cohort studies. Eur Heart J. 2017;

38:2478–2486.

11. Hirata A, Sugiyama D, Watanabe M, et al. Association of extremely

high levels of high-density lipoprotein cholesterol with cardiovascular

mortality in a pooled analysis of 9 cohort studies including 43,407 individuals: The EPOCH-JAPAN study. J Clin Lipidol. 2018;12:

674–684.e5.

12. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res. 1993;

34:1255–1274.

13. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:

2109–2122.

Takaeko et al

HDL cholesterol and endothelial function

14. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;

367:2089–2099.

15. Lincoff AM, Nicholls SJ, Riesmeyer JS, et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med. 2017;

376:1933–1942.

16. Group HTRC, Bowman L, Hopewell JC, et al. Effects of anacetrapib

in patients with atherosclerotic vascular disease. N Engl J Med. 2017;

377:1217–1227.

17. Vitali C, Khetarpal SA, Rader DJ. HDL cholesterol metabolism and

the risk of CHD: new insights from human genetics. Curr Cardiol

Rep. 2017;19:132.

18. Zanoni P, Khetarpal SA, Larach DB, et al. Rare variant in scavenger

receptor BI raises HDL cholesterol and increases risk of coronary

heart disease. Science. 2016;351:1166–1171.

19. Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med.

1999;340:115–126.

20. Higashi Y, Noma K, Yoshizumi M, Kihara Y. Endothelial function

and oxidative stress in cardiovascular diseases. Circ J. 2009;73:

411–418.

21. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the

ultrasound assessment of endothelial-dependent flow-mediated

vasodilation of the brachial artery: a report of the International

Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;

39:257–265.

22. Benjamin EJ, Larson MG, Keyes MJ, et al. Clinical correlates and heritability of flow-mediated dilation in the community: the Framingham

Heart Study. Circulation. 2004;109:613–619.

23. Donald AE, Halcox JP, Charakida M, et al. Methodological approaches to optimize reproducibility and power in clinical studies of

flow-mediated dilation. J Am Coll Cardiol. 2008;51:1959–1964.

24. Modena MG, Bonetti L, Coppi F, Bursi F, Rossi R. Prognostic role of

reversible endothelial dysfunction in hypertensive postmenopausal

women. J Am Coll Cardiol. 2002;40:505–510.

25. Yeboah J, Folsom AR, Burke GL, et al. Predictive value of brachial

flow-mediated dilation for incident cardiovascular events in a

population-based study: the multi-ethnic study of atherosclerosis. Circulation. 2009;120:502–509.

26. Maruhashi T, Soga J, Fujimura N, et al. Relationship between flowmediated vasodilation and cardiovascular risk factors in a large

community-based study. Heart. 2013;99:1837–1842.

27. Kajikawa M, Maruhashi T, Matsumoto T, et al. Relationship between

serum triglyceride levels and endothelial function in a large

community-based study. Atherosclerosis. 2016;249:70–75.

28. Gokce N, Keaney JF Jr., Hunter LM, Watkins MT, Menzoian JO,

Vita JA. Risk stratification for postoperative cardiovascular events

via noninvasive assessment of endothelial function: a prospective

study. Circulation. 2002;105:1567–1572.

29. American Diabetes Association: clinical practice recommendations

1999. Diabetes Care. 1999;22(Suppl 1):S1–S114.

30. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and

treatment of high blood cholesterol in adults (adult treatment panel

III). JAMA. 2001;285:2486–2497.

31. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H,

Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–1847.

32. Moriyama Y, Okamura T, Inazu A, et al. A low prevalence of coronary

heart disease among subjects with increased high-density lipoprotein

cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. Prev Med. 1998;27:659–667.

33. Simic B, Hermann M, Shaw SG, et al. Torcetrapib impairs endothelial

function in hypertension. Eur Heart J. 2012;33:1615–1624.

34. Luscher TF, Taddei S, Kaski JC, et al. Vascular effects and safety

of dalcetrapib in patients with or at risk of coronary heart disease:

the dal-VESSEL randomized clinical trial. Eur Heart J. 2012;33:

857–865.

671

35. Besler C, Heinrich K, Rohrer L, et al. Mechanisms underlying adverse

effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest. 2011;121:2693–2708.

36. Carvalho LS, Panzoldo N, Santos SN, et al. HDL levels and oxidizability during myocardial infarction are associated with reduced

endothelial-mediated vasodilation and nitric oxide bioavailability.

Atherosclerosis. 2014;237:840–846.

37. Adams V, Besler C, Fischer T, et al. Exercise training in patients with

chronic heart failure promotes restoration of high-density lipoprotein

functional properties. Circ Res. 2013;113:1345–1355.

38. Sorrentino SA, Besler C, Rohrer L, et al. Endothelial-vasoprotective

effects of high-density lipoprotein are impaired in patients with type

2 diabetes mellitus but are improved after extended-release niacin

therapy. Circulation. 2010;121:110–122.

39. Weissglas-Volkov D, Pajukanta P. Genetic causes of high and low

serum HDL-cholesterol. J Lipid Res. 2010;51:2032–2057.

40. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation

study. Lancet. 2012;380:572–580.

41. Inazu A, Brown ML, Hesler CB, et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene

mutation. N Engl J Med. 1990;323:1234–1238.

42. Koizumi J, Mabuchi H, Yoshimura A, et al. Deficiency of serum

cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemia. Atherosclerosis. 1985;58:175–186.

43. Maruyama T, Sakai N, Ishigami M, et al. Prevalence and phenotypic

spectrum of cholesteryl ester transfer protein gene mutations in Japanese hyperalphalipoproteinemia. Atherosclerosis. 2003;166:177–185.

44. Saito F. A pedigree of homozygous familial hyperalphalipoproteinemia. Metabolism. 1984;33:629–633.

45. Hirano K-I, Nagasaka H, Kobayashi K, et al. Disease-associated

marked hyperalphalipoproteinemia. Mol Genet Metab Rep. 2014;1:

264–268.

46. Zhong S, Sharp DS, Grove JS, et al. Increased coronary heart disease

in Japanese-American men with mutation in the cholesteryl ester

transfer protein gene despite increased HDL levels. J Clin Invest.

1996;97:2917–2923.

47. Agerholm-Larsen B, Nordestgaard BG, Steffensen R, Jensen G,

Tybjaerg-Hansen A. Elevated HDL cholesterol is a risk factor for

ischemic heart disease in white women when caused by a common

mutation in the cholesteryl ester transfer protein gene. Circulation.

2000;101:1907–1912.

48. Hirano K, Yamashita S, Nakajima N, et al. Genetic cholesteryl ester

transfer protein deficiency is extremely frequent in the Omagari area

of Japan. Marked hyperalphalipoproteinemia caused by CETP gene

mutation is not associated with longevity. Arterioscler Thromb Vasc

Biol. 1997;17:1053–1059.

49. Yamashita S, Sprecher DL, Sakai N, Matsuzawa Y, Tarui S,

Hui DY. Accumulation of apolipoprotein E-rich high density lipoproteins in hyperalphalipoproteinemic human subjects with plasma

cholesteryl ester transfer protein deficiency. J Clin Invest. 1990;

86:688–695.

50. Sakai N, Yamashita S, Hirano K, et al. Decreased affinity of low density lipoprotein (LDL) particles for LDL receptors in patients with

cholesteryl ester transfer protein deficiency. Eur J Clin Invest. 1995;

25:332–339.

51. Ishigami M, Yamashita S, Sakai N, et al. Large and cholesteryl esterrich high-density lipoproteins in cholesteryl ester transfer protein

(CETP) deficiency can not protect macrophages from cholesterol

accumulation induced by acetylated low-density lipoproteins. J Biochem. 1994;116:257–262.

52. Matsuura F, Wang N, Chen W, Jiang XC, Tall AR. HDL from CETPdeficient subjects shows enhanced ability to promote cholesterol efflux

from macrophages in an apoE- and ABCG1-dependent pathway. J

Clin Invest. 2006;116:1435–1442.

53. Gomaraschi M, Ossoli A, Pozzi S, et al. eNOS activation by HDL is

impaired in genetic CETP deficiency. PLoS One. 2014;9:e95925.

672

54. Hirata T, Sugiyama D, Nagasawa SY, et al. A pooled analysis of the

association of isolated low levels of high-density lipoprotein cholesterol with cardiovascular mortality in Japan. Eur J Epidemiol. 2017;

32:547–557.

55. Ernst N, Fisher M, Smith W, et al. The association of plasma highdensity lipoprotein cholesterol with dietary intake and alcohol

Journal of Clinical Lipidology, Vol 13, No 4, August 2019

consumption. The Lipid Research Clinics Prevalence Study. Circulation. 1980;62:Iv41–Iv52.

56. Oda N, Kajikawa M, Maruhashi T, et al. Endothelial function is

impaired in relation to alcohol intake even in the case of light alcohol

consumption in Asian men; Flow-mediated Dilation Japan (FMD-J)

Study. Int J Cardiol. 2017;230:523–528.

Takaeko et al

Table S1

HDL cholesterol and endothelial function

672.e1

Clinical characteristics in propensity score matched subjects

Variables

Age, y

Body mass index, kg/m2

Systolic blood pressure, mmHg

Diastolic blood pressure, mmHg

Heart rate, bpm

Total cholesterol, mg/dL

Triglycerides, mg/dL

HDL-C, mg/dL

LDL-C, mg/dL

Glucose, mg/dL

Medications, n (%)

Anti-hypertensive therapy

Anti-hyperglycemic therapy

Framingham risk score, %

Medical history, n (%)

Hypertension

Dyslipidemia

Diabetes mellitus

Current smokers

Previous cardiovascular disease

High 60–79 mg/dL

(n 5 451)

Extremely high $80 mg/dL

(n 5 451)

P value

51.4 6 11

22.1 6 2.6

129 6 17

81 6 12

63 6 11

216 6 32

84 (64, 109)

68 6 6

129 6 29

101 6 20

51.5 6 11

22.0 6 2.6

129 6 17

80 6 12

63 6 12

213 6 30

77 (58, 110)

91 6 11

105 6 28

100 6 17

.892

.623

.695

.239

.956

.138

.021

,.001

,.001

.500

98 (21.7)

19 (4.2)

4.0 6 3.5

104 (23.1)

18 (4.0)

3.1 6 3.4

.632

.867

,.001

200

165

29

127

12

203

86

24

131

16

.841

,.001

.479

.768

.442

(44.4)

(36.6)

(6.4)

(28.2)

(2.7)

(45.0)

(19.1)

(5.3)

(29.1)

(3.6)

HDL-C indicates high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.

Data are presented as mean 6 SD or median (interquartile range).

Figure S1 Scatter plot shows the relationship between flowmediated vasodilation (FMD) and high-density lipoprotein cholesterol (HDL-C). Red line represents the estimated Lowest

smoothed curve.

Figure S2 Bar graphs show flow-mediated vasodilation (FMD)

in high levels of high-density lipoprotein cholesterol (HDL-C)

and in extreme high levels of HDL-C in propensity score matched

subjects. The error bars indicate the standard deviation.

...